|
Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Tuesday's Exclusive Article
These 3 Psychedelic Stocks Activated After Trump's Executive OrderSubmitted by Nathan Reiff. Article Published: 4/27/2026. 
Key Points
- The Trump administration's recent order in support of psychedelic drug treatments for various mental health conditions has prompted spikes of as much as nearly 80% for some of the companies in this space.
- Firms like Compass Pathways, AtaiBeckley, and Definium Therapeutics could see their drug candidates reach approval and commercialization much faster.
- PSIL is a broad exchange-traded fund offering access to the wider psychedelics industry for investors not keen to take on risk associated with a single speculative company.
- Special Report: Elon Musk already made me a “wealthy man”
The Trump administration's April 2026 executive order supporting psychedelic drugs may have flown under the radar for many investors amid the Iran war and other high-profile domestic news, but its implications for this small—yet growing—industry are significant. Within days the FDA began acting, awarding priority vouchers to select companies developing these therapies and thereby shortening review timelines. Single-session wins were to be expected for some of the larger players in the psychedelics space, and several stocks did indeed spike. Over the longer term, however, developers will need to prove their drugs can deliver clinical benefit and commercial traction. Here are a few companies worth watching. A Promising Candidate Could Reach Market Sooner, Easing Financial Pressure
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just revealed 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - are competing for a role in what Wall Street is calling 'Project Apex,' a potential $1.75 trillion listing Bloomberg has dubbed the biggest of all time.
Dr. Mark Skousen, Macroeconomic Strategist at The Oxford Club, says a pre-IPO 'backdoor' entry still exists - and nearly 15,000 investors have already accessed his free recommendation. June is the reported target date, and the window is narrowing. Get Dr. Skousen's free SpaceX pre-IPO recommendation before June
One of the biggest beneficiaries of the executive order was biotech firm Compass Pathways (NASDAQ: CMPS), whose shares have jumped nearly 80% in the past month. The excitement centers on COMP360, a drug candidate for treatment-resistant depression that received a priority voucher. Compass has struggled to balance operations while advancing a promising program. The company has posted mounting net losses, and losses per share have widened even as weighted-average basic shares outstanding have more than doubled in recent years. A faster route to commercialization for COMP360 could materially improve Compass's outlook. The firm was already covered by several analysts as a Buy, and the executive order prompted a fresh wave of bullish ratings and price-target increases. As of late April, eight of 10 analyst ratings are Buy and consensus forecasts imply over 100% upside, even after the recent rally. Another Speculative Penny Stock With a Promising CandidateClinical-stage biotech AtaiBeckley (NASDAQ: ATAI) also rallied in mid-April. Its BPL-003 program—targeting certain forms of depression—won’t begin Phase 3 until later in 2026, but the company reported positive earlier-phase results in April. With current annual sales of only about $4 million, AtaiBeckley carries a very high price-to-sales (P/S) ratio in the 400s, which ordinarily signals a richly valued stock. The company is pre-profit and trades as a penny stock, with shares below $5 even after the recent lift—factors that make ATAI a speculative and potentially volatile investment. Still, momentum behind psychedelic therapies could accelerate BPL-003’s path to market. Ten of 12 analysts rate the stock favorably, and a consensus price target of $14.63 implies more than 200% upside, a much larger projected gain than Compass. A Potential Generalized Anxiety Disorder Treatment and Strong Analyst SupportDefinium Therapeutics Inc. (NASDAQ: DFTX), formerly Mind Medicine, has also reported significant net losses, but it finished 2025 with $258 million in cash and equivalents—giving it runway to advance MM120, a candidate for generalized anxiety disorder. Like the other programs mentioned, MM120 targets a very large potential market; successful commercialization could elevate Definium from a speculative name to a meaningful biopharma competitor. DFTX shares have risen roughly 25% in the last month amid the executive order news. Analysts appear relatively bullish: the stock has 14 Buy ratings and one Sell, with consensus forecasts pointing to roughly 70% upside. If exposure to individual psychedelic biotechs feels too risky, investors can gain diversified access through a focused exchange-traded fund such as the AdvisorShares Psychedelics ETF (NYSEARCA: PSIL). The fund is actively managed—which helps explain its relatively high 1% expense ratio—but it offers immediate exposure to roughly two dozen companies in the space. That diversification can capture upside when a company achieves a breakthrough and help cushion the blow when trials disappoint. PSIL also currently offers a dividend yield near 8.5%, which may appeal to income-minded investors. |
0 Response to "We're excited to have you on board"
Post a Comment